WordNet

an impairment of health or a condition of abnormal functioning
a hemoprotein composed of globin and heme that gives red blood cells their characteristic color; function primarily to transport oxygen from the lungs to the body tissues; "fish have simpler hemoglobin than mammals" (同)haemoglobin, Hb
caused by or altered by or manifesting disease or pathology; "diseased tonsils"; "a morbid growth"; "pathologic tissue"; "pathological bodily processes" (同)morbid, pathologic, pathological
the 19th letter of the Roman alphabet (同)s

PrepTutorEJDIC

(体の)『病気』,疾患 / (精神・道徳などの)病気,病弊
女性の話術芸人 =diseur
ヘモグロビン,血色素
病気にかかった / 病的な,不健全な(morbid)
sulfurの化学記号 / {略}South[ern]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. ヘモグロビン変異の概要 introduction to hemoglobin mutations
2. 異型鎌状赤血球症候群 variant sickle cell syndromes
3. 鎌状赤血球障害の診断 diagnosis of sickle cell disorders
4. 鎌状赤血球形質 sickle cell trait
5. 鎌状赤血球症を有する女性における妊娠 pregnancy in women with sickle cell disease

English Journal

Fetal hemoglobin in sickle cell anemia.

Nadkarni A1, Dabke P2, Colah RB2, Ghosh K2.
Blood cells, molecules & diseases.Blood Cells Mol Dis.2014 Apr;52(4):175. doi: 10.1016/j.bcmd.2013.11.007. Epub 2013 Dec 17.
PMID 24355765

Does Erythropoietin Have a Role in the Treatment of β-Hemoglobinopathies?

Fibach E1, Rachmilewitz EA2.Author information 1Department of Hematology, Hadassah-Hebrew University Medical Center, Ein-Kerem, Jerusalem 91120, Israel. Electronic address: Fibach@yahoo.com.2Department of Hematology, Wolfson Medical Center, Holon 58100, Israel.AbstractThis review presents the indications and contraindications (pros and cons) for the potential use of erythropoietin (Epo) as a treatment in β-thalassemia and sickle cell anemia (SCA). Its high cost and route of administration (by injection) are obvious obstacles, especially in underdeveloped countries, where thalassemia is prevalent. We believe that from the data summarized in this review, the time has come to define, by studying in vitro and in vivo models, as well as by controlled clinical trials, the rationale for treating patients with various forms of thalassemia and SCA with Epo alone or in combination with other medications.
Hematology/oncology clinics of North America.Hematol Oncol Clin North Am.2014 Apr;28(2):249-263. doi: 10.1016/j.hoc.2013.11.002. Epub 2014 Jan 24.
This review presents the indications and contraindications (pros and cons) for the potential use of erythropoietin (Epo) as a treatment in β-thalassemia and sickle cell anemia (SCA). Its high cost and route of administration (by injection) are obvious obstacles, especially in underdeveloped countri
PMID 24589265

Targeted Fetal Hemoglobin Induction for Treatment of Beta Hemoglobinopathies.

Perrine SP1, Pace BS2, Faller DV3.Author information 1Hemoglobinopathy-Thalassemia Research Unit, Cancer Center, Department of Medicine, Pediatrics, Pharmacology and Experimental Therapeutics, Boston University School of Medicine, 72 East Concord Street, L-909, Boston, MA 02118, USA. Electronic address: sperrine@bu.edu.2Department of Pediatrics and Biochemistry and Molecular Biology, Georgia Regents University, Augusta, GA 30912, USA.3Cancer Center, Boston University School of Medicine, Boston, MA 02118, USA.AbstractFetal globin (gamma globin; HBG) is normally expressed during fetal life and prevents the clinical manifestations of beta hemoglobinopathies before birth. HBG genes are normally integrated in hematopoietic stem cells in all humans, and are at least partially amenable to reactivation. Inducing expression of fetal globin (HBG) gene expression to 60% to 70% of alpha globin synthesis produces a β-thalassemia trait phenotype, and reduces anemia. Tailoring combinations of therapeutics to patient subsets characterized for quantitative trait loci which modulate basal fetal hemoglobin and erythroid cell survival should provide effective amelioration of clinical symptoms in β-thalassemia and sickle cell disease.
Hematology/oncology clinics of North America.Hematol Oncol Clin North Am.2014 Apr;28(2):233-248. doi: 10.1016/j.hoc.2013.11.009.
Fetal globin (gamma globin; HBG) is normally expressed during fetal life and prevents the clinical manifestations of beta hemoglobinopathies before birth. HBG genes are normally integrated in hematopoietic stem cells in all humans, and are at least partially amenable to reactivation. Inducing expres
PMID 24589264

Japanese Journal

Use of Proton Pump Inhibitors Is Associated With Anemia in Cardiovascular Outpatients

Shikata Toshiyuki,Sasaki Naoko,Ueda Masahiro [他]
Circulation journal : official journal of the Japanese Circulation Society 79(1), 193-200, 2015-01
NAID 40020311976

第IX・XI・XII因子低下を伴う高齢者後天性血友病A

羽生直史,青田泰雄,後藤明彦,櫻井道雄
日本老年医学会雑誌 52(3), 285-290, 2015
後天性血友病は凝固第VIII因子に対する自己抗体による出血傾向を認める比較的稀な疾患である．基礎疾患として，自己免疫疾患や腫瘍性疾患などを認めることが報告され，高齢者に比較的多い．英国での発症頻度は年間100万人あたり1.48人と報告されており，原因不明の出血をみたら，疑うべき疾患の1つである．症例は84歳の女性．皮下出血とHb低下のため近医より紹介受診した．著明な貧血とAPTT延長を認め濃厚赤血 …
NAID 130005093069

Association between Pulse Wave Velocity and Coronary Artery Calcification in Japanese men:the Shiga Epidemiological Study of Subclinical Atherosclerosis (SESSA)

Torii Sayuki,Arima Hisatomi,Ohkubo Takayoshi,Fujiyoshi Akira,Kadota Aya,Takashima Naoyuki,Kadowaki Sayaka,Hisamatsu Takashi,Saito Yoshino,Miyagawa Naoko,Zaid Maryam,Murakami Yoshitaka,Abbott Robert D.,Horie Minoru,Miura Katsuyuki,Ueshima Hirotsugu,for the SESSA Research Group
Journal of Atherosclerosis and Thrombosis advpub(0), 2015
… Coronary artery calcification (CAC) is an intermediate stage in the process leading to overt cardiovascular disease (CVD) and an established determinant of coro nary artery disease. …
NAID 130005092229